BIOGEN INC. Operating Leases, Rent Expense
BIOGEN INC. (BIIB) reported Operating Leases, Rent Expense of $64.50 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-02-06
- BIOGEN INC. operating leases, rent expense for fiscal 2018 was $64.50M, a 1.23% decline from fiscal 2017.
- BIOGEN INC. operating leases, rent expense for fiscal 2017 was $65.30M, a 4.95% decline from fiscal 2016.
- BIOGEN INC. operating leases, rent expense for fiscal 2016 was $68.70M, a 0.15% increase from fiscal 2015.
- BIOGEN INC. operating leases, rent expense for fiscal 2015 was $68.60M, a 9.94% increase from fiscal 2014.
| Period end | Operating Leases, Rent Expense 12 month |
|---|---|
| 2018-12-31 | $64.50M 10-K · filed 2019-02-06 |
| 2017-12-31 | $65.30M 10-K · filed 2019-02-06 |
| 2016-12-31 | $68.70M 10-K · filed 2019-02-06 |
| 2015-12-31 | $68.60M 10-K · filed 2018-02-01 |
| 2014-12-31 | $62.40M 10-K · filed 2017-02-02 |
| 2013-12-31 | $56.10M 10-K · filed 2016-02-03 |
| 2012-12-31 | $49.00M 10-K · filed 2015-02-04 |
| 2011-12-31 | $46.20M 10-K · filed 2014-02-06 |
| 2010-12-31 | $44.80M 10-K · filed 2013-02-05 |
| 2009-12-31 | $36.40M 10-K · filed 2012-02-03 |
| 2008-12-31 | $36.00M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |